1. Scrip
  2. >>New Products

Morphosys/Incyte’s Monjuvi Wins Early US FDA Approval In Second-Line DLBCL

MAb’s CAR-T Like Efficacy Seen Giving Wide Adoption

 
• By Sten Stovall

Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.    

Lymphoma
MorphoSys, Incyte to co-commercialize Monjuvi in the US • Source: Shutterstock

Commercial supplies of Incyte Corporation and MorphoSys AG’s novel CD19-targeting monoclonal antibody will be available in the US by the end of this week after Monjuvi (tafasitamab) won early approval there as a second-line treatment of relapsed or refractory diffuse large B-cell lymphoma. The companies said the patient population size they would be initially targeting there was around 10,000 per annum.

The CD19-directed cytolytic antibody is now indicated as a second-line therapy in combination with Celgene’s Revlimid (lenalidomide) for adult patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Stealth Bio Bags Elamipretide FDA Win After Multiple Setbacks

 
• By Sushmita Panda

Stealth won FDA accelerated approval for Forzinity, the first Barth syndrome therapy, after multiple regulatory setbacks. The decision sets the stage for confirmatory trials and expanded patient access.

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sanofi’s Pipeline Pressure Continues As Tolebrutinib Trips Near Finish Line

 
• By Manas Mishra

Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.

Merck Scores US FDA Approval For Subcutaneous Keytruda Qlex

 
• By Alaric DeArment

The agency approved the subcutaneous formulation of the PD-1 inhibitor, months after approving a subcutaneous version of BMS’s Opdivo.

More from Scrip

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

 
• By Kevin Grogan

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 
• By Alexandra Shimmings

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.